Anti-CD11a monoclonal antibody M17

Drug Profile

Anti-CD11a monoclonal antibody M17

Alternative Names: Monoclonal antibody M17/4.4; Monoclonal antibody M17/; Monoclonal antibody M17/5.2

Latest Information Update: 15 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Bristol-Myers Squibb; Merck & Co
  • Class Monoclonal antibodies
  • Mechanism of Action CD11a antigen antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Transplant rejection

Most Recent Events

  • 01 Sep 1998 No-Development-Reported for Transplant rejection in USA (Unknown route)
  • 10 Dec 1996 A study has been added to the Transplant rejection pharmacodynamics section
  • 28 Aug 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top